Eli Lilly plans to submit tirzepatide application at the end of the year

After presenting new results from a comparison study between Eli Lilly's tirzepatide and diabetes drug Lantus, the company is ready to set a time horizon for when it will seek approval for the drug (Updated).

Photo: Mike Segar/Reuters/Ritzau Scanpix

A recent study conducted by Eli Lilly shows positive effects of the use of diabetes drug tirzepatide.

In fact, all primary study outcomes were met in the trial that compared the effect of tirzepatide with the older treatment insulin glargine – also known by the brand name Lantus.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs